Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > stealth guidance failure

<< Previous

Bullboard Posts

Next >>

Post by lscfaon Aug 29, 2022 11:04am

225 Views

Post# 34926702

stealth guidance failure

co. tried to signal to market that the upfront payment is substantial by announcing a lot of new spending initiatives......

However, it did not explicitly state that there is no need for near term financing......

So cynical investors think the news on new initiatives is an attempt to pump the stock to do a financing.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023